Subscribe To
Sanofi, regeneron shares pop on big news about copd treatment
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.6...
March 27, 2023, 1:26 pm
Could this label expansion be a growth catalyst for sanofi stock?
dupixent was proven to be effective at treating a condition that causes chronic hives. The indication c...
March 25, 2023, 8:43 am
Regeneron's (regn) dupixent meets pivotal copd study goal, up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with ...
March 24, 2023, 4:00 pm
Regeneron's dupixent shows promise as copd treatment
CNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug dupixent has shown promise in t...
March 23, 2023, 6:37 pm
Sanofi's (sny) dupixent meets goal in pivotal copd study
Sanofi (SNY) and partner Regeneron's (REGN) dupixent led to a 30% decline in exacerbations per a late-s...
March 23, 2023, 3:14 pm
Sanofi, regeneron shares pop more than 6% after data shows asthma drug dupixent may also treat copd
Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectat...
March 23, 2023, 2:31 pm
Why shares of regeneron are rising thursday
If dupixent is approved to treat COPD, it will be the seventh indication for the drug. Regeneron's sale...
March 23, 2023, 12:08 pm
Sanofi's blockbuster dupixent drug clears major trial
French pharma multinational Sanofi's dupixent drug has achieved impressive results in a late-stage tria...
March 23, 2023, 10:43 am
Regn stock alert: regeneron pharmaceuticals gains on dupixent drug data
Regeneron Pharmaceuticals (NASDAQ: REGN ) stock is on the rise Thursday after the company released its latest data on ...
March 23, 2023, 10:43 am
Regeneron, sanofi soar on blow-out results in 'smoker's lung'
Sanofi and Regeneron's asthma drug dupixent succeeded in a study of patients with "smoker's lung," lead...
March 23, 2023, 9:03 am
Sanofi's (sny) dupixent gets eu nod for eczema in young kids
Sanofi (SNY) and Regeneron's dupixent becomes the first and only targeted medicine approved to treat se...
March 21, 2023, 7:42 am
Regeneron (regn) gains 9.3% in a year: will the uptrend last?
Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in ...
March 17, 2023, 1:45 pm
dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (csu) in adults and adolescents aged 12 years and older accepted for fda review
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, March 07, 2023 (GLOB...
March 7, 2023, 6:00 am
Can sanofi (sny) keep the beat streak alive in q4 earnings?
Sanofi's (SNY) top line is likely to have been driven by higher sales of dupixent and vaccines....
January 31, 2023, 8:45 am
Will eylea and dupixent fuel regeneron's (regn) q4 earnings?
Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and ...
January 30, 2023, 12:48 pm
dupixent® (dupilumab) approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Approximately 60% of patients aged 12 years and older treated with dupixent 300 mg weekly in the pivota...
January 30, 2023, 6:00 am
Regeneron, sanofi's dupixent is one step closer to approval for young children in europe
Shares of Regeneron Pharmaceuticals Inc. REGN, +0.15% gained about 2.5% in premarket trading on Friday after the European Medicines Agency's Committee...
January 27, 2023, 8:27 am
dupixent® (dupilumab) recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis
If approved, dupixent would be the first and only targeted medicine in the EU for these young children ...
January 27, 2023, 5:59 am
What's in store for regeneron pharmaceuticals (regn) in 2023?
Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and ...
January 3, 2023, 1:32 pm
Sanofi's (sny) dupixent & vaccines make the stock attractive
One can invest in Sanofi (SNY) due to the strong performance of dupixent, above-market sales growth of ...
December 27, 2022, 12:02 pm